CMIC Co, Ltd. Japan
14
5
8
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
57%
8 trials in Phase 3/4
100%
5 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Pediatric Patients Aged 4 to 11 Years With APDS
Role: collaborator
TAMBE Japan Post-Marketing Surveillance
Role: collaborator
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Role: collaborator
TBE Zone 2 PMS in Japan
Role: collaborator
Pediatric Patients Aged 1 to 6 Years With APDS
Role: collaborator
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
Role: collaborator
LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis
Role: collaborator
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Role: collaborator
An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS
Role: collaborator
Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds
Role: collaborator
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Role: collaborator
DS-5565 Phase III Study for Renal Impairment in Japanese Subjects
Role: collaborator
DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain
Role: collaborator
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Role: collaborator
All 14 trials loaded